Zusammenfassung
Die Hyperandrogenämie wird als die vermehrte Produktion und Ausschüttung von Androgenen definiert. Dabei kann die Klinik, mit der sich die Patientin an uns wendet, sehr vielfältig sein.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
Literatur
Amer SA, Banu Z, Li TC, Cooke ID (2002) Long-term follow-up of patients with polycystic ovary syndrome after laparoscopic ovarian drilling: endocrine and ultrasonographic outcomes. Hum Reprod 17: 2851–2857
Andoh K, Mizunuma H, Liu X, Kanijo T, Yamada K, Ibuki Y (1998) A comparative study of fixed-dose, step-down, and low dose step-up regimens of human menopausal gonadotropin for patients with polycystic ovary syndrome. Fertil Steril 70: 840–846
Apridonidze T, Essah PA, Iuorno MJ, Nestler JE (2005) Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 90: 1929–1935
Bidet M, Bellanné-Chantelot C, Galand-Portier MB Tardy V, Billaud L, Laborde K, Coussieu C, Morel Y, Vaury C, Golmard JL, Claustre A, Mornet E, Chakhtoura Z, Mowszowicz I, Bachelot A, Touraine P, Kuttenn F (2009) Clincal and molecular characterization of a cohort of 161 unrelated omen with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency and 330 family members. J Clin Endocrinol Metab 94: 1570–578
Bouhanna P (2003) Androgenetic alopecia: Combining medical and surgical treatments. Dermatol Surg 29: 1130–1134
Burkman RT Jr (1995) The role of oral contraceptives in the treatment of hyperandrogenic disorders. Am J Med 98: 130S–136S
Cordera F, Grant C, van Heerden J, Thompson G, Young W (2003) Androgen- secreting adrenal tumors. Surgery 134: 874–880
Dunaif A (1997) Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 18: 774–800
Dunaif A, Segal KR, Futterweit W, Dobrjansky A (1989) Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38: 1165–1174
Eijkemans MJ, Imani B, Mulders AG, Habbema JD, Fauser BC (2003) High singleton live birth rate following classical ovulation induction in normogonadotrophic anovulatory infertility (WHO 2). Hum Reprod 18: 2357–2362
Eisenhardt S, Schwarzmann N, Henschel V, Germayer A, von Wolff M, Hamann A, Strowitzki T (2006) Early effects of metformin in women with polycystic ovary syndrome: a prospective randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab 91: 946–952
Elter K, Imir G, Durmusoglu F (2002) Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovary syndrome: a randomized controlled study. Hum Reprod 17: 1729–1737
EscobarMorreale HF (2010) Diagnosis and management of hirsutism. Ann NY Acad Sci 1205: 166–174
Fassnacht M, Schlenz N, Schneider SB, Wudy SA, Allolio B, Arlt W (2003) Beyond adrenal and ovarian androgen generation: Increased peripheral 5 alpha-reductase activity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88: 2760–2766
Ferriman D, Gallway JD (1961) Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 21: 1440–1447
Hardiman P, Pillay OC, Atiomo W (2003) Polycystic ovary syndrome and endometrial carcinoma. Lancet 361: 1810–1812
Hoellen F, Noack F, Ribbat J, Kelling K, Diedrich K, Bohlmann MK (2011) Androgenproduzierende Tumoren. Gynäkologische Endokrinologie 9: 109–116
Homburg R, Lambalk CB (2004) Polycystic ovary syndrome in adolescence – a therapeutic conundrum. Hum Reprod 19: 1039–1042
Hornung M, Vogel P, Schubert T, Schlitt HJ, Bolder U (2008) A case of virilization induced by a Krukenberg tumor from gastric cancer. World J Surg Oncol 6: 196
Karimzadeh MA, Javedani M (2010) An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate-metformin in patients with polycystic ovary syndrome. Fertil Steril 94: 216–220
Ludwig M (2010) Gynäkologische Endokrinologie – Ein Handbuch für die Praxis, 1. Aufl. Optimist Fachbuchverlag Hamburg
Mavropoulos JC, Yancy WS, Hepburn J, Westman EC (2005) The effects of a low-carbohydrate, ketogenic diet on the polycystic ovary syndrome: a pilot study. Nutr Metab 2: 35
Mukherjee S, Sharma S, Chakravarty BN (2010) Comparative evaluation of pregnancy outcome in gonadotropin-clomiphene combination vs clomiphene alone in polycystic ovary syndrome and unexplained infertility – A prospective clinical trial. J Hum Reprod Sci 3: 80–84
New MI (2004) An update of congenital adrenal hyperplasia. Ann NY Acad Sci 1038: 14–43
Palomba S, Orio F, Zullo F (2006) Ovulation induction in women with polycystic ovary syndrome. Fertil Steril 86 (Suppl 1): S26-S27
Pierroz DD, Aebi AC, Huhtaniemi IT, Aubert ML (1999) Many LH peaks are needed to physiologically stimulated testosterone secretion: modulation by fasting and NPY. Am J Physiol 276: E603-E610
Plewig G (2005) Akne und Rosazea. In: Braun-Falco O, Plewig G, Wolff HH, Burgdorf W, Landthaler M (Hrsg) Dermatologie und Venerologie, Kap 61. Springer, Berlin Heidelberg New York, S 890
Price VH (2003) Androgenetic alopecia in women. J Invest Dermatol Symp Proc 8: 24–27
Ratts VS, Pauls RN, Pinto AB, Kraja A, Williams DB, Odem RR (2007) Risk of multiple gestation after ovulation induction in polycystic ovary syndrome. J Reprod Med 52: 896–900
Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related ton polycystic ovary syndrome. Fertil Steril 81: 19–25
Rushton DH (2002) Nutritional factors and hair loss. Clin Exp Dermatol 27: 396–404
Siegenthaler W, Kaufmann W, Hornborstel H, Waller HD (1992) Lehrbuch der Inneren Medizin. Thieme, Stuttgart New York, S 337–350
Sinclair R, Wewerinke M, Jolley D (2005) Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol 152: 466–473
Speiser PW, White PC (2003) Congenital adrenal hyperplasia. N. Engl J Med 349: 776–788
Stadtmauer LA, Sarhan A, Duran EH, Beydoun H, Bocca S, Pultz B, Oehringer S (2011) The impact of a gonadotropin-releasing hormone antagonist on gonadotropin ovulation induction cycles in women with polycystic ovary syndrome: a prospective randomized study. Fertil Steril 95: 216: 220
Volek JS, Fernandez ML, Feinman RD, Phinney SD (2008) Dietary carbohydrate restriction induces a unique metabolic state positively affecting therogenic dyslipidemia, fatty acid partitioning, and metabolic syndrome. Prog Lipid Res 47: 307–318
Witchel FS, Azziz R (2010) Nonclassic congenital adrenal hyperplasia. Int J Pediatr Endocrinol 2010: 625105. Epub 2010 Jun 30
Wolf JE Jr, Shander D, Huber F, Jackson J, Lin CS, Mathes BM, Schrode K (2007) Randomized, double-blind clinical evaluation oft he efficiacy and safety of topical eflornithine HCl 13.9%cream in the treatment of facial hair. Int J Dermatol 46: 94–98
Wolff H (2005) Erkrankungen der Haare. In: Braun-Falco O, Plewig G, Wolff HH, Burgdorf W, Landthaler M (Hrsg) Dermatologie und Venerologie, Kap 63. Springer, Berlin Heidelberg New York, S 943
Young J, Tardy V, de la Perrière AB, Bachelot A, Morel Y; French Society of Endocrinology (2010) Detection and management of late-onset 21-hydroxylase deficiency in women with hyperandrogenism. Ann Endocrinol (Paris) 71 (1): 14–18
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Banz-Jansen, C. (2013). Hyperandrogenämie. In: Diedrich, K., Ludwig, M., Griesinger, G. (eds) Reproduktionsmedizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-30181-0_6
Download citation
DOI: https://doi.org/10.1007/978-3-642-30181-0_6
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-30180-3
Online ISBN: 978-3-642-30181-0
eBook Packages: Medicine (German Language)